Does Aduhelm mark the return of science-based medicine?

<p>"While we still lack a complete cause and effect model of Alzheimer’s disease, there is no doubt that the etiology is multifaceted and nonlinear. This accounts for the fact that it takes an incredibly long time for Alzheimer’s disease to develop. I mention this because one of the major problems with FDA approval has always been that it insists on utilizing the same framework and methodology of approving drugs designed to treat long-term diseases as it would with short-term diseases."</p> <p>Robert Trent is a graduate student who blogs at <a href= "http://medaphysics.com/" target="_blank" rel= "noopener nofollow">Medaphysics</a>.</p> <p>He shares his story and discusses his KevinMD article, "<a href= "https://www.kevinmd.com/blog/2021/07/does-the-fda-approval-of-aducanumab-mark-the-return-of-science-based-medicine.html" target="_blank" rel="noopener">Does the FDA approval of aducanumab mark the return of science-based medicine?</a>" (<a href= "https://www.kevinmd.com/blog/2021/07/does-the-fda-approval-of-aducanumab-mark-the-return-of-science-based-medicine.html">https://www.kevinmd.com/blog/2021/07/does-the-fda-approval-of-aducanumab-mark-the-return-of-science-based-medicine.html</a>)</p>